{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:00:23Z","timestamp":1782918023270,"version":"3.54.5"},"reference-count":168,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,1,1]]},"DOI":"10.2169\/internalmedicine.4846-24","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T17:13:47Z","timestamp":1734542027000},"page":"46-66","source":"Crossref","is-referenced-by-count":4,"title":["Migraine Management in Japan: Current Approaches and Science Narrative Including an Evidence-based Review"],"prefix":"10.2169","volume":"65","author":[{"given":"Takao","family":"Takeshima","sequence":"first","affiliation":[{"name":"Department of Neurology, Headache Center, Tominaga Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kikui","sequence":"additional","affiliation":[{"name":"Department of Neurology, Headache Center, Tominaga Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Danno","sequence":"additional","affiliation":[{"name":"Department of Neurology, Headache Center, Tominaga Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Headache Clinical Practice Guideline Development Committee. Clinical Practice Guideline for Headache Disorders 2021. Japanese Society of Neurology, Japanese Headache Society, Japanese Society of Neurological Therapeutics, Eds. Igaku-Shoin, Tokyo, 2021."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Ashina M, Terwindt GM, Al-Karagholi MA, et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397: 1496-1504, 2021.","DOI":"10.1016\/S0140-6736(20)32162-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain 20: 111, 2019.","DOI":"10.1186\/s10194-019-1062-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Araki N, Takeshima T, Ando N, et al. Clinical practice guideline for chronic headache 2013. Neurol Clin Neurosci 7: 231-259, 2019.","DOI":"10.1111\/ncn3.12322"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38: 1-211, 2018.","DOI":"10.1177\/0333102417738202"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Awaki E, Takeshima T, Matsumori Y, et al. Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study. Neurol Ther 13: 165-182, 2024.","DOI":"10.1007\/s40120-023-00569-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain 21: 110, 2020.","DOI":"10.1186\/s10194-020-01180-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache 58 (Suppl 1): 4-16, 2018.","DOI":"10.1111\/head.13300"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Edvinsson L, Haanes KA. Views on migraine pathophysiology: where does it start? Neurol Clin Neurosci 8: 120-127, 2019.","DOI":"10.1111\/ncn3.12356"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Blau JN. Migraine: theories of pathogenesis. Lancet 339: 1202-1207, 1992.","DOI":"10.1016\/0140-6736(92)91140-4"},{"key":"11","unstructured":"11. Takeshima T. The Secrets of Headache Treatment. Maruzen, Tokyo, 2014."},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88: 41-52, 2000.","DOI":"10.1016\/S0304-3959(00)00305-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12: 963-974, 2003.","DOI":"10.1023\/A:1026119331193"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache 38: 295-302, 1998.","DOI":"10.1046\/j.1526-4610.1998.3804295.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84: 422-435, 2009.","DOI":"10.4065\/84.5.422"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013: Cd008040, 2013.","DOI":"10.1002\/14651858.CD008614.pub2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Suthisisang C, Poolsup N, Kittikulsuth W, Pudchakan P, Wiwatpanich P. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 41: 1782-1791, 2007.","DOI":"10.1345\/aph.1K121"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 50: 808-818, 2010.","DOI":"10.1111\/j.1526-4610.2010.01635.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013: Cd008041, 2013.","DOI":"10.1002\/14651858.CD008041.pub3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 70: 1555-1563, 2008.","DOI":"10.1212\/01.wnl.0000310638.54698.36"},{"key":"21","unstructured":"21. Al-Waili NS. Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur J Med Res 5: 176-182, 2000."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser MG. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 58: 1660-1665, 2002.","DOI":"10.1212\/WNL.58.11.1660"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Zhao D, Chen Z, Hu S, et al. Efficacy and safety of loxoprofen hydrogel transdermal patch versus loxoprofen tablet in Chinese patients with myalgia: a double-blind, double-dummy, parallel-group, randomized, controlled, non-inferiority trial. Clin Drug Investig 39: 369-377, 2019.","DOI":"10.1007\/s40261-019-00756-x"},{"key":"24","unstructured":"24. Loo CY, Tan HJ, Teh HS, Raymond AA. Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J 48: 834-839, 2007."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012: Cd008615, 2012.","DOI":"10.1002\/14651858.CD008615.pub2"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012: Cd009665, 2012.","DOI":"10.1002\/14651858.CD009665"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012: Cd009663, 2012.","DOI":"10.1002\/14651858.CD009663"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 48: 236-247, 2008.","DOI":"10.1111\/j.1526-4610.2007.01007.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dodick DW, Lipton RB, Goadsby PJ, et al. Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database. Headache 48: 184-193, 2008.","DOI":"10.1111\/j.1526-4610.2007.00868.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Smith LA, Oldman AD, McQuay HJ, Moore RA. WITHDRAWN: Eletriptan for acute migraine. Cochrane Database Syst Rev 2001: Cd003224, 2007.","DOI":"10.1002\/14651858.CD003224.pub2"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. L\u00e1inez MJ. Rizatriptan in the treatment of migraine. Neuropsychiatr Dis Treat 2: 247-259, 2006.","DOI":"10.2147\/nedt.2006.2.3.247"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Ferrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia 21: 129-136, 2001.","DOI":"10.1046\/j.1468-2982.2001.00169.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Tfelt-Hansen PC. Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register. J Headache Pain 12: 399-403, 2011.","DOI":"10.1007\/s10194-011-0327-3"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Goadsby PJ, Classey JD. Evidence for serotonin (5-HT) <sub>1B<\/sub>, 5-HT<sub>1D<\/sub> and 5-HT<sub>1F<\/sub> receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122: 491-498, 2003.","DOI":"10.1016\/S0306-4522(03)00570-0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Shepheard S, Edvinsson L. Possible antimigraine mechanisms of action of the 5HT<sub>1F<\/sub> receptor agonist LY334370. Cephalalgia 19: 851-858, 1999.","DOI":"10.1046\/j.1468-2982.1999.1910851.x"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT<sub>1F<\/sub> receptor agonist lasmiditan. Cephalalgia 30: 1159-1169, 2010.","DOI":"10.1177\/0333102410370873"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Labastida-Ram\u00edrez A, Rubio-Beltr\u00e1n E, Haanes KA, et al. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain 161: 1092-1099, 2020.","DOI":"10.1097\/j.pain.0000000000001801"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Edvinsson JCA, Maddahi A, Christiansen IM, et al. Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT<sub>1<\/sub> receptors. J Headache Pain 23: 26, 2022.","DOI":"10.1186\/s10194-022-01394-z"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Vila-Pueyo M, Page K, Murdock PR, et al. The selective 5-HT<sub>1F<\/sub> receptor agonist lasmiditan inhibits trigeminal nociceptive processing: implications for migraine and cluster headache. Br J Pharmacol 179: 358-370, 2022.","DOI":"10.1111\/bph.15699"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Ferrari MD, F\u00e4rkkil\u00e4 M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT<sub>1F<\/sub> receptor agonist lasmiditan - a randomised proof-of-concept trial. Cephalalgia 30: 1170-1178, 2010.","DOI":"10.1177\/0333102410375512"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142: 1894-1904, 2019.","DOI":"10.1093\/brain\/awz134"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42. Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology 91: e2222-e2232, 2018.","DOI":"10.1212\/WNL.0000000000006641"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Shapiro RE, Hochstetler HM, Dennehy EB, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain 20: 90, 2019.","DOI":"10.1186\/s10194-019-1044-6"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Reuter U, Krege JH, Lombard L, et al. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: findings from the CENTURION study. Cephalalgia 42: 20-30, 2022.","DOI":"10.1177\/03331024211048507"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Knievel K, Buchanan AS, Lombard L, et al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia 40: 19-27, 2020.","DOI":"10.1177\/0333102419889350"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Krege JH, Lipton RB, Baygani SK, Komori M, Ryan SM, Vincent M. Lasmiditan for patients with migraine and contraindications to triptans: a post hoc analysis. Pain Ther 11: 701-712, 2022.","DOI":"10.1007\/s40122-022-00388-8"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Brandes JL, Klise S, Krege JH, et al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 39: 1343-1357, 2019.","DOI":"10.1177\/0333102419864132"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Tepper SJ, Krege JH, Lombard L, et al. Characterization of dizziness after lasmiditan usage: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials. Headache 59: 1052-1062, 2019.","DOI":"10.1111\/head.13544"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Martin VT, Ahmed Z, Hochstetler HM, et al. Tolerability and safety of lasmiditan treatment in elderly patients with migraine: post hoc analyses from randomized studies. Clin Ther 43: 1066-1078, 2021.","DOI":"10.1016\/j.clinthera.2021.04.004"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Tassorelli C, Bragg S, Krege JH, et al. Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine. J Headache Pain 22: 132, 2021.","DOI":"10.1186\/s10194-021-01343-2"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Loo LS, Plato BM, Turner IM, et al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol 19: 191, 2019.","DOI":"10.1186\/s12883-019-1420-5"},{"key":"52","doi-asserted-by":"publisher","unstructured":"52. Ashina M, Reuter U, Smith T, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia 41: 294-304, 2021.","DOI":"10.1177\/0333102421989232"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 38: 184-190, 1998.","DOI":"10.1046\/j.1526-4610.1998.3803184.x"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache 61: 755-765, 2021.","DOI":"10.1111\/head.14122"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Pearlman EM, Wilbraham D, Dennehy EB, et al. Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol 35: e2732, 2020.","DOI":"10.1002\/hup.2732"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Saengjaroentham C, Strother LC, Dripps I, et al. Differential medication overuse risk of novel anti-migraine therapeutics. Brain 143: 2681-2688, 2020.","DOI":"10.1093\/brain\/awaa211"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: from pathophysiology to treatment. J Neurol 270: 3654-3666, 2023.","DOI":"10.1007\/s00415-023-11706-1"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med 381: 2230-2241, 2019.","DOI":"10.1056\/NEJMoa1813049"},{"key":"59","doi-asserted-by":"publisher","unstructured":"59. Scott LJ. Ubrogepant: first approval. Drugs 80: 323-328, 2020.","DOI":"10.1007\/s40265-020-01264-5"},{"key":"60","doi-asserted-by":"publisher","unstructured":"60. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322: 1887-1898, 2019.","DOI":"10.1001\/jama.2019.16711"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache 60: 141-152, 2020.","DOI":"10.1111\/head.13682"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Chiang CC, Arca KN, Dunn RB, et al. Real-world efficacy, tolerability, and safety of ubrogepant. Headache 61: 620-627, 2021.","DOI":"10.1111\/head.14062"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Wang Q, Wang S, Zhu Y, Lin F. Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials. Front Neurol 14: 1205778, 2023.","DOI":"10.3389\/fneur.2023.1205778"},{"key":"64","doi-asserted-by":"publisher","unstructured":"64. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394: 737-745, 2019.","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397: 51-60, 2021.","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol 19: 727-737, 2020.","DOI":"10.1016\/S1474-4422(20)30234-9"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Lipton RB, Pozo-Rosich P, Blumenfeld AM, et al. Effect of atogepant for preventive migraine treatment on patient-reported outcomes in the randomized, double-blind, phase 3 ADVANCE trial. Neurology 100: e764-e777, 2023.","DOI":"10.1212\/WNL.0000000000201568"},{"key":"68","doi-asserted-by":"publisher","unstructured":"68. Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402: 775-785, 2023.","DOI":"10.1016\/S0140-6736(23)01049-8"},{"key":"69","unstructured":"69. AbbVie. Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants with Migraine (ECLIPSE) [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06241313"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain 13 (Suppl 2): S31-S70, 2012.","DOI":"10.1007\/s10194-012-0437-6"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Anneken K, Evers S, Husstedt IW. Efficacy of fixed combinations of acetylsalicyclic acid, acetaminophen and caffeine in the treatment of idiopathic headache: a review. Eur J Neurol 17: 534-e525, 2010.","DOI":"10.1111\/j.1468-1331.2009.02922.x"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Ferrari M, Hann J, Charles A, Dodick DW, Sakai F. Oxford Textbook of Headache Syndromes. Oxford University Press, Oxford, 2020: 1-546.","DOI":"10.1093\/med\/9780198724322.001.0001"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Jackson JL, Cogbill E, Santana-Davila R, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLOS ONE 10: e0130733, 2015.","DOI":"10.1371\/journal.pone.0130733"},{"key":"74","unstructured":"74. Goto F, Tashiro K, Kutsuzawa N. Early phase II clinical trial on the clinical effect of KB-2796 for migraine. Yakuri To Chiryo (Jpn Pharmacol Ther) 22: 5031-5047, 1994 (in Japanese)."},{"key":"75","unstructured":"75. Goto F, Tashiro K, Kutsuzawa N. Late phase II clinical trial on the clinical evaluation of KB-2796 (lomerizine hydrochloride) for migraine. Rinsho Hyoka (Clin Eval) 23: 13-37, 1995 (in Japanese)."},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Imai N, Konishi T, Serizawa M, Okabe T. Do the effects of long-term lomerizine administration differ with age? Intern Med 46: 683-684, 2007.","DOI":"10.2169\/internalmedicine.46.6409"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Chu MK, Wang SJ. Nomenclature for flunarizine, cinnarizine, and lomerizine. Cephalalgia 40: 321-322, 2020.","DOI":"10.1177\/0333102420902175"},{"key":"78","doi-asserted-by":"publisher","unstructured":"78. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA 250: 2500-2502, 1983.","DOI":"10.1001\/jama.250.18.2500"},{"key":"79","doi-asserted-by":"publisher","unstructured":"79. Markley HG, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 34: 973-976, 1984.","DOI":"10.1212\/WNL.34.7.973"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013: Cd010611, 2013.","DOI":"10.1002\/14651858.CD010611"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Takeshima T, Suzuki N, Matsumori Y, et al. Effectiveness and safety of an extended-release tablet of sodium valproate for the prophylactic treatment of migraine: postmarketing surveillance in Japan. Neurol Clin Neurosci 4: 134-141, 2016.","DOI":"10.1111\/ncn3.12053"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 362: 2185-2193, 2010.","DOI":"10.1056\/NEJMoa0907328"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014: Cd010236, 2014.","DOI":"10.1002\/14651858.CD010236.pub2"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013: Cd010610, 2013.","DOI":"10.1002\/14651858.CD010610"},{"key":"85","doi-asserted-by":"publisher","unstructured":"85. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27: 814-823, 2007.","DOI":"10.1111\/j.1468-2982.2007.01326.x"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47: 170-180, 2007.","DOI":"10.1111\/j.1526-4610.2006.00684.x"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013: Cd010609, 2013.","DOI":"10.1002\/14651858.CD010609"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78: 1337-1345, 2012.","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev Cd003225, 2004.","DOI":"10.1002\/14651858.CD003225.pub2"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Martin SR, Foley MR. Approach to the pregnant patient with headache. Clin Obstet Gynecol 48: 2-11, 2005.","DOI":"10.1097\/01.grf.0000153208.93620.39"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Silberstein SD. Headaches in pregnancy. J Headache Pain 6: 172-174, 2005.","DOI":"10.1007\/s10194-005-0176-z"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Xu XM, Liu Y, Dong MX, Zou DZ, Wei YD. Tricyclic antidepressants for preventing migraine in adults. Medicine (Baltimore) 96: e6989, 2017.","DOI":"10.1097\/MD.0000000000006989"},{"key":"93","doi-asserted-by":"publisher","unstructured":"93. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45: 144-152, 2005.","DOI":"10.1111\/j.1526-4610.2005.05029.x"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Hedayat M, Nazarbaghi S, Heidari M, Sharifi H. Venlafaxine can reduce the migraine attacks as well as amitriptyline: a noninferiority randomized trial. Clin Neurol Neurosurg 214: 107151, 2022.","DOI":"10.1016\/j.clineuro.2022.107151"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 107: 44-48, 2004.","DOI":"10.1016\/j.clineuro.2004.03.004"},{"key":"96","doi-asserted-by":"publisher","unstructured":"96. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 322: 19-22, 2001.","DOI":"10.1136\/bmj.322.7277.19"},{"key":"97","doi-asserted-by":"publisher","unstructured":"97. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289: 65-69, 2003.","DOI":"10.1001\/jama.289.1.65"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Diener HC, Gendolla A, Feuersenger A, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia 29: 921-927, 2009.","DOI":"10.1111\/j.1468-2982.2008.01825.x"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Odaguchi H, Wakasugi A, Ito H, et al. The efficacy of goshuyuto, a typical Kampo (Japanese herbal medicine) formula, in preventing episodes of headache. Curr Med Res Opin 22: 1587-1597, 2006.","DOI":"10.1185\/030079906X112769"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Mitsufuji T, Araki N, Ito Y, et al. Protocol paper: effects of yokukansan on medication-overuse headache. Neurol Clin Neurosci 7: 119-121, 2019.","DOI":"10.1111\/ncn3.12284"},{"key":"101","unstructured":"101. Tsutsui S, Nishuzawa M, Hashimoto S, Abe T. Effects of dimetotiazine in the prophylactic treatment of migraine in its long-term management. Toho Igakkai Zasshi (J Med Soc Toho Univ) 28: 240-245, 1981 (in Japanese)."},{"key":"102","doi-asserted-by":"publisher","unstructured":"102. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50: 466-470, 1998.","DOI":"10.1212\/WNL.50.2.466"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Talebian A, Soltani B, Banafshe HR, Moosavi GA, Talebian M, Soltani S. Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial. Electron Physician 10: 6279-6285, 2018.","DOI":"10.19082\/6279"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. MacLennan SC, Wade FM, Forrest KM, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol 23: 1300-1304, 2008.","DOI":"10.1177\/0883073808318053"},{"key":"105","doi-asserted-by":"publisher","unstructured":"105. Bruijn J, Duivenvoorden H, Passchier J, Locher H, Dijkstra N, Arts WF. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia 30: 1426-1434, 2010.","DOI":"10.1177\/0333102410365106"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86: 1818-1826, 2016.","DOI":"10.1212\/WNL.0000000000002560"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Jimenez XF, Sundararajan T, Covington EC. A systematic review of atypical antipsychotics in chronic pain management: olanzapine demonstrates potential in central sensitization, fibromyalgia, and headache\/migraine. Clin J Pain 34: 585-591, 2018.","DOI":"10.1097\/AJP.0000000000000567"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. Silberstein SD, Peres MF, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 42: 515-518, 2002.","DOI":"10.1046\/j.1526-4610.2002.02126.x"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109. Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: a systematic review. Medicine (Baltimore) 98: e14099, 2019.","DOI":"10.1097\/MD.0000000000014099"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110. Gon\u00e7alves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MF. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry 87: 1127-1132, 2016.","DOI":"10.1136\/jnnp-2016-313458"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111. Chabi A, Zhang Y, Jackson S, et al. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia 35: 379-388, 2015.","DOI":"10.1177\/0333102414544979"},{"key":"112","unstructured":"112. Nagata E, Yasuda T, Moriya Y, Netsu S, Takizawa S. The effect of orexin receptor antagonist for migraine prophylaxis. Nihon Zutsu Gakkaishi (Jpn J Headache) 5: 164-167, 2018 (in Japanese, Abstract in English)."},{"key":"113","doi-asserted-by":"crossref","unstructured":"113. Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: a phase 2 randomized controlled clinical trial. Cephalalgia Rep 3: 1-10, 2020.","DOI":"10.1177\/2515816320932573"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114. Igarashi H, Shibata M, Ozeki A, Day KA, Matsumura T. Early onset and maintenance effect of galcanezumab in japanese patients with episodic migraine. J Pain Res 14: 3555-3564, 2021.","DOI":"10.2147\/JPR.S326905"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115. Dodick DW, Doty EG, Aurora SK, et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41: 340-352, 2021.","DOI":"10.1177\/0333102420966658"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116. Lipton RB, Buse DC, Sandoe CH, et al. Changes in migraine interictal burden following treatment with galcanezumab: results from a phase III randomized, placebo-controlled study. Headache 63: 683-691, 2023.","DOI":"10.1111\/head.14460"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117. Hirata K, Takeshima T, Sakai F, et al. A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf 20: 721-733, 2021.","DOI":"10.1080\/14740338.2021.1866536"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118. Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther 356: 223-231, 2016.","DOI":"10.1124\/jpet.115.227793"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119. Cohen JM, Ning X, Kessler Y, et al. Immunogenicity of biologic therapies for migraine: a review of current evidence. J Headache Pain 22: 3, 2021.","DOI":"10.1186\/s10194-020-01211-5"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120. Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 377: 2123-2132, 2017.","DOI":"10.1056\/NEJMoa1705848"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121. Takeshima T, Sakai F, Hirata K, et al. Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 61: 927-935, 2021.","DOI":"10.1111\/head.14138"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122. Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28: 1716-1725, 2021.","DOI":"10.1111\/ene.14715"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123. Reuter U, McClure C, Liebler E, Pozo-Rosich P. Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. J Neurol Psychiatry 90: 796-804, 2019.","DOI":"10.1136\/jnnp-2018-320113"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124. Friedman DI, Cohen JM. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine. Emerg Top Life Sci 4: 179-190, 2020.","DOI":"10.1042\/ETLS20200018"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125. Ohlsson L, Kronvall E, Stratton J, Edvinsson L. Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. J Headache Pain 19: 66, 2018.","DOI":"10.1186\/s10194-018-0905-8"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126. Cohen-Barak O, Weiss S, Rasamoelisolo M, et al. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia 38: 1960-1971, 2018.","DOI":"10.1177\/0333102418771376"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127. Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14: 1081-1090, 2015.","DOI":"10.1016\/S1474-4422(15)00249-5"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14: 1091-1100, 2015.","DOI":"10.1016\/S1474-4422(15)00245-8"},{"key":"129","doi-asserted-by":"publisher","unstructured":"129. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319: 1999-2008, 2018.","DOI":"10.1001\/jama.2018.4853"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377: 2113-2122, 2017.","DOI":"10.1056\/NEJMoa1709038"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394: 1030-1040, 2019.","DOI":"10.1016\/S0140-6736(19)31946-4"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132. Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology 95: e2487-e2499, 2020.","DOI":"10.1212\/WNL.0000000000010600"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133. Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61: 1102-1111, 2021.","DOI":"10.1111\/head.14178"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134. Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61: 1092-1101, 2021.","DOI":"10.1111\/head.14169"},{"key":"135","unstructured":"135. Ministry of Health, Labour and Welfare (published 2021) Guidelines for promotion of optimal use of fremanezumab [Internet]. [cited 2025 Oct 31]. Available from: https:\/\/www.pmda.go.jp\/files\/000248992.pdf (in Japanese)"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136. Gangula PR, Dong YL, Wimalawansa SJ, Yallampalli C. Infusion of pregnant rats with calcitonin gene-related peptide (CGRP) <sub>8-37<\/sub>, a CGRP receptor antagonist, increases blood pressure and fetal mortality and decreases fetal growth. Biol Reprod 67: 624-629, 2002.","DOI":"10.1095\/biolreprod67.2.624"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137. Noseda R, Bedussi F, Gobbi C, Zecca C, Ceschi A. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. Cephalalgia 41: 789-798, 2021.","DOI":"10.1177\/0333102420983292"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138. Greene KA, Gentile CP, Szperka CL, et al. Calcitonin gene-related peptide monoclonal antibody use for the preventive treatment of refractory headache disorders in adolescents. Pediatr Neurol 114: 62-67, 2021.","DOI":"10.1016\/j.pediatrneurol.2020.09.014"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139. Szperka CL, VanderPluym J, Orr SL, et al. Recommendations on the use of anti-CGRP monoclonal antibodies in children and adolescents. Headache 58: 1658-1669, 2018.","DOI":"10.1111\/head.13414"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140. Medrea I, Christie S, Tepper SJ, Thavorn K, Hutton B. Effects of acute and preventive therapies for episodic and chronic cluster headache: a scoping review of the literature. Headache 62: 329-362, 2022.","DOI":"10.1111\/head.14284"},{"key":"141","unstructured":"141. Taylor FR. ABC&apos;s of Headache Trigger Management [Internet]. [cited 2024 Feb 5]. Available from: https:\/\/americanmigrainefoundation.org\/resource-library\/headache-trigger-management\/"},{"key":"142","doi-asserted-by":"publisher","unstructured":"142. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 27: 394-402, 2007.","DOI":"10.1111\/j.1468-2982.2007.01303.x"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143. Robbins L. Precipitating factors in migraine: a retrospective review of 494 patients. Headache 34: 214-216, 1994.","DOI":"10.1111\/j.1526-4610.1994.hed3404214.x"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144. Takeshima T, Ishizaki K, Fukuhara Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache 44: 8-19, 2004.","DOI":"10.1111\/j.1526-4610.2004.04004.x"},{"key":"145","doi-asserted-by":"publisher","unstructured":"145. Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 53: 65-72, 1993.","DOI":"10.1016\/0304-3959(93)90057-V"},{"key":"146","unstructured":"146. Sakai F. Zutsu-taisou [Internet]. [cited 2025 Oct 31]. Available from: https:\/\/www.jhsnet.net\/pdf\/zutu_taisou.pdf"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147. Seng EK, Martin PR, Houle TT. Lifestyle factors and migraine. Lancet Neurol 21: 911-921, 2022.","DOI":"10.1016\/S1474-4422(22)00211-3"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148. Seng EK, Gosnell I, Sutton L, Grinberg AS. Behavioral management of episodic migraine: maintaining a healthy consistent lifestyle. Curr Pain Headache Rep 26: 247-252, 2022.","DOI":"10.1007\/s11916-022-01023-z"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149. Varangot-Reille C, Suso-Mart\u00ed L, Romero-Palau M, Su\u00e1rez-Pastor P, Cuenca-Mart\u00ednez F. Effects of different therapeutic exercise modalities on migraine or tension-type headache: a systematic review and meta-analysis with a replicability analysis. J Pain 23: 1099-1122, 2022.","DOI":"10.1016\/j.jpain.2021.12.003"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150. Woldeamanuel YW, Oliveira ABD. What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials. J Headache Pain 23: 134, 2022.","DOI":"10.1186\/s10194-022-01503-y"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151. La Touche R, Fierro-Marrero J, S\u00e1nchez-Ru\u00edz I, et al. Prescription of therapeutic exercise in migraine, an evidence-based clinical practice guideline. J Headache Pain 24: 68, 2023.","DOI":"10.1186\/s10194-023-01571-8"},{"key":"152","unstructured":"152. Tassorelli C, Grazzi L, de Tommaso M, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology 91: e364-e373, 2018."},{"key":"153","doi-asserted-by":"publisher","unstructured":"153. Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study. Neurology 87: 529-538, 2016.","DOI":"10.1212\/WNL.0000000000002918"},{"key":"154","doi-asserted-by":"publisher","unstructured":"154. Henssen D, Derks B, van Doorn M, et al. Vagus nerve stimulation for primary headache disorders: an anatomical review to explain a clinical phenomenon. Cephalalgia 39: 1180-1194, 2019.","DOI":"10.1177\/0333102419833076"},{"key":"155","doi-asserted-by":"publisher","unstructured":"155. Oshinsky ML, Murphy AL, Hekierski H Jr, Cooper M, Simon BJ. Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia. Pain 155: 1037-1042, 2014.","DOI":"10.1016\/j.pain.2014.02.009"},{"key":"156","doi-asserted-by":"publisher","unstructured":"156. Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial. Cephalalgia 39: 3-14, 2019.","DOI":"10.1177\/0333102418811573"},{"key":"157","doi-asserted-by":"crossref","unstructured":"157. Danno D, Iigaya M, Imai N, Igarashi H, Takeshima T. The safety and preventive effects of a supraorbital transcutaneous stimulator in Japanese migraine patients. Sci Rep 9: 9900, 2019.","DOI":"10.1038\/s41598-019-46044-8"},{"key":"158","doi-asserted-by":"publisher","unstructured":"158. Magis D, D&apos;Ostilio K, Thibaut A, et al. Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia 37: 881-891, 2017.","DOI":"10.1177\/0333102416656118"},{"key":"159","doi-asserted-by":"crossref","unstructured":"159. Magis D, Sava S, d&apos;Elia TS, Baschi R, Schoenen J. Safety and patients&apos; satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly<sup>\u00ae<\/sup> device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain 14: 95, 2013.","DOI":"10.1186\/1129-2377-14-95"},{"key":"160","doi-asserted-by":"crossref","unstructured":"160. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 9: 373-380, 2010.","DOI":"10.1016\/S1474-4422(10)70054-5"},{"key":"161","doi-asserted-by":"publisher","unstructured":"161. Starling AJ, Tepper SJ, Marmura MJ, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 38: 1038-1048, 2018.","DOI":"10.1177\/0333102418762525"},{"key":"162","doi-asserted-by":"crossref","unstructured":"162. Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ. Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain 139: 2002-2014, 2016.","DOI":"10.1093\/brain\/aww118"},{"key":"163","doi-asserted-by":"crossref","unstructured":"163. Daniel O, Sharon R, Tepper SJ. A device review of Relivion<sup>\u00ae<\/sup>: an external combined occipital and trigeminal neurostimulation (eCOT-NS) system for self-administered treatment of migraine and major depressive disorder. Expert Rev Med Devices 18: 333-342, 2021.","DOI":"10.1080\/17434440.2021.1908122"},{"key":"164","unstructured":"164. Isabella Ciccone. FDA Approves Theranica&apos;s Nerivio for Preventive Treatment of Migraine. NeurologyLive [Internet]. [cited 2024 Sep 23]. Available from: https:\/\/www.neurologylive.com\/view\/fda-approves-theranica-nerivio-preventive-treatment-migraine"},{"key":"165","doi-asserted-by":"crossref","unstructured":"165. Babaei M, Rapoport AM. Device profile of Nerivio for the acute and preventive treatment of episodic or chronic migraine in patients 12 years and older. Expert Rev Med Devices 20: 433-447, 2023.","DOI":"10.1080\/17434440.2023.2202815"},{"key":"166","doi-asserted-by":"crossref","unstructured":"166. Yarnitsky D, Dodick DW, Grosberg BM, et al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache 59: 1240-1252, 2019.","DOI":"10.1111\/head.13551"},{"key":"167","doi-asserted-by":"crossref","unstructured":"167. Puledda F, Shields K. Non-pharmacological approaches for migraine. Neurotherapeutics 15: 336-345, 2018.","DOI":"10.1007\/s13311-018-0623-6"},{"key":"168","doi-asserted-by":"crossref","unstructured":"168. Holroyd KA, Cottrell CK, O&apos;Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 341: c4871, 2010.","DOI":"10.1136\/bmj.c4871"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_4846-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T03:26:39Z","timestamp":1767410799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_4846-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":168,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4846-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"4846-24"}}